Recent Updates
Recently added Catalysts
CTMX

CytomX Therapeutics to Present at Cowen 42nd Annual Healthcare Conference

Key Takeaway: SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will participate in a virtual panel discussion at the Cowen 42nd Annual Healthcare Conference on Monday, March 7, 2022 at 12:50 p.m. ET.
A live webcast of the panel will be available on the Events and Presentations page of CytomX’s website at www.cytomx.com. An archived replay will be available on the CytomX website for 30 days following the event. In addition, management will be available for one-on-one meetings with investors who are registered to attend the conference.
About CytomX Therapeutics, Inc.
Probody is a U.S. registered trademark of CytomX Therapeutics, Inc.
VP, Investor Relations & Corp. Communications
Direct: (650) 273-4999
Director, Corporate Communications
Direct: (650) 528 2929
Last updated: Feb 28, 2022